A B2B cannabis supply agreement with a Canadian Licensed Producer defines the product specifications, pricing, delivery obligations, quality standards, and compliance responsibilities between the LP and the international importer or domestic distributor. Getting the structure right before the first shipment protects both parties and prevents the most common causes of contract disputes: specification creep, batch rejection disputes, and export permit delays.
This guide covers the core clauses every international importer should review before signing with a Canadian LP. It addresses the compliance elements that Health Canada's Cannabis Act and the Cannabis Regulations impose on export supply chains. It also covers the practical terms experienced importers negotiate in Germany, Australia, and Israel.
Core clauses every cannabis supply agreement must contain
Most international cannabis supply disputes trace back to the same root: a contract drafted quickly, with ambiguous product specs and no clarity on who owns the compliance risk at each stage of the export chain. A well-structured agreement removes that ambiguity before it becomes a customs hold or a rejected shipment.
Product specifications and batch tolerances
Define the strain, format (dried flower, pre-roll, or extract), targeted cannabinoid range, moisture content limit, and harvest or trim standard. Include a tolerance band, not just a target. A batch delivered at 26% THC when the target was 30% may be compliant under Canadian law but commercially unsellable in a pharmacy channel that dispensed against the original spec sheet.
For hand-trimmed flower specifically, define what "hand-trimmed" means: no mechanical tumbler finishing, stems under 3mm, and a minimum bud size threshold. Vague trim quality language generates more post-delivery disputes than any other clause.
Certificate of Analysis requirements
Every shipment should arrive with a full batch COA from an ISO/IEC 17025-accredited laboratory. Required analyte panels include: cannabinoid potency, terpene profile, water activity, heavy metals, pesticide residues, microbial contamination, and mycotoxins. German and Australian regulators require specific panels that exceed the Canadian baseline. Confirm the testing scope against destination-country requirements before finalising this clause.
Specify the COA review and dispute window in the contract. Importers typically have 5 to 14 business days from delivery to raise a COA dispute. After that window closes, the batch is deemed accepted.
Pricing, currency, and payment terms
Cannabis B2B contracts in the international channel are typically priced in Canadian dollars, US dollars, or Euros. Pricing in Euros removes currency risk for European importers but introduces it for the LP. The agreement should specify the currency, the FX reference rate used for conversion, payment terms (30, 60, or 90 days from delivery confirmation), and any price-escalation clause tied to production cost indices.
If you want assurance the LP isn't offering better pricing to a competing importer in the same market, include a most-favoured-nation clause and define its scope clearly.
Exclusivity and territorial rights
Some importers negotiate territorial exclusivity: the LP agrees not to supply other parties in the same country for the same product or strain. This is common in Germany, where pharmacy distributors invest significantly in regulatory onboarding. If exclusivity is included, define its scope by strain, product format, and geography. Attach performance conditions: minimum purchase volumes the importer must meet to maintain the exclusive position.
Export compliance obligations under the Cannabis Act
Under Canada's Cannabis Act and the Cannabis Regulations, a Licensed Producer must hold a valid export authorisation before any shipment leaves Canada. Health Canada issues this authorisation on a per-shipment basis, and processing takes 4 to 8 weeks from application. The supply agreement must address this timeline explicitly.
Who applies for the export permit
The LP applies for the Canadian export permit. On the importer's side, obtaining the necessary import permit or narcotic authorisation in the destination country is your responsibility. The agreement should confirm this division: the LP warrants it will apply for each export permit within a defined number of business days after purchase order confirmation, and you warrant you'll provide destination-country import documentation within a parallel window.
If either party misses the permit timeline, the contract should specify whether the shipment date shifts automatically (most common) or whether a formal breach notice and cure period applies.
Export permit failure clause
Export permits can be refused or delayed, particularly for novel destination markets or where the Health Canada file has incomplete documentation. Define what happens when a permit application is denied: does the order cancel, defer to the next window, or hold? Clarify which party bears storage and re-testing costs if the product must be held while the permit is reapplied for.
Packaging and labelling compliance
Canadian export packaging must simultaneously comply with the Cannabis Regulations and the destination country's labelling requirements. For Germany, Bundesopiumstelle requires specific narcotic identification markings. For Australia, the TGA requires product and sponsor declarations on the outer packaging. Specify who is responsible for dual-labelling and who bears the cost of a re-label if a regulatory requirement changes between contract execution and shipment. See the full export packaging requirements guide for detail on each market's specifications.
Single Convention compliance
Cannabis is a Schedule I narcotic under the Single Convention on Narcotic Drugs, administered internationally by the International Narcotics Control Board. Both parties are bound by the respective national frameworks implementing the Convention. Representation and warranty clauses should confirm both parties are lawfully licensed in their respective jurisdictions at the time of each shipment, not only at signing.
Market-specific regulatory addenda
A single master supply agreement governs the commercial relationship, but each destination market needs a regulatory addendum. These are not optional extras. They define the documentation, testing, and labelling obligations that apply to each shipment and protect both parties when a customs authority requests compliance evidence.
Germany
German pharmaceutical importers require EU-GMP documentation from their Canadian supplier, or a Health Canada GMP certificate accepted under the Mutual Recognition Agreement between Canada and the EU. Read the full Germany cannabis export guide for the complete documentation checklist.
The German addendum should specify:
- The LP's current GMP certification status and an obligation to notify the importer within 5 business days of any certificate suspension or inspection findings
- The Bundesopiumstelle narcotic import permit number to be confirmed before each shipment
- The required COA analyte panel for German pharmacy distributor acceptance (full terpene profile, microbials, residual solvents, heavy metals)
- The narcotic declaration required under the Medizinal-Cannabisgesetz
Incomplete EU-GMP file submissions are the most common cause of first-shipment delays from Canadian LPs into the German medical channel. Require the LP to provide a complete GMP documentation package before the first purchase order is issued, not after.
Australia
The Australian addendum must reference the TGO 93 standard, the mandatory quality standard for medicinal cannabis imported into Australia. The addendum should confirm:
- Batch testing meets or exceeds TGO 93 specifications for each analyte
- The Therapeutic Goods Administration product approval reference for each SKU being imported
- The Office of Drug Control import permit number for each shipment
- Compliance with the Therapeutic Goods Act 1989 and the Customs Regulations 1956
For the full Australian supply chain compliance picture, see the Australian cannabis export guide.
Israel
Israeli pharmaceutical importers operate under the Israel Medical Cannabis Agency framework, which requires IMC-GMP certification. Your Israeli addendum should address the pre-import approval requirement, traceability documentation aligned with IMC-GAP standards, and packaging under Israel's narcotics import protocol.
Israel places more regulatory burden on the importer than Germany or Australia does. The supply agreement should reflect this: place IMC documentation obligations on the importer while requiring the LP to provide the underlying batch data in the format the Israeli authority requires.
Offtake structures, price reviews, and termination
The commercial backbone of a supply agreement is the offtake structure: what volumes are committed, how prices adjust over time, and what happens when production or regulatory conditions shift.
Structuring the offtake commitment
Offtake terms vary by relationship maturity. A first-contract importer typically negotiates a non-binding forecast with a committed minimum per shipment. An established distribution partner may commit to quarterly minimums with annual volume escalators. Balance the LP's need for production planning certainty against your need for flexibility in a market where pharmacy volumes shift with prescriber behaviour.
Three common offtake structures in the B2B cannabis channel:
- Spot purchase: No volume commitment. Order-by-order pricing. Suitable for trial relationships or market entry.
- Blanket purchase order: Committed annual or quarterly volume at agreed pricing, drawn down through individual release orders. Gives the LP production certainty without locking the importer into rigid delivery schedules.
- Exclusive supply agreement: The LP reserves capacity for one importer in a defined market. Requires meaningful minimum volume commitments in return.
Price escalation and review provisions
Multi-year supply agreements should include a price review mechanism tied to an objective index: production cost inflation, Health Canada fee schedule changes, or currency movement beyond a defined band. Without a price review clause, the LP bears all input cost risk for the contract term. That makes a meaningful multi-year commitment difficult to offer, and difficult to hold.
Force majeure in a regulated industry
Standard force majeure clauses cover natural disasters and acts of government. In a cannabis supply context, extend the definition explicitly to: Health Canada regulatory changes that suspend or restrict export authorisations, destination-country changes that affect import permit availability, and facility-level compliance holds triggered by a Health Canada inspection. These events are foreseeable in a licensed industry and should be carved out separately from standard force majeure language.
Also specify whether a regulatory suspension on one product affects the entire agreement or only the suspended SKU.
Termination and wind-down
Include a staged termination provision: notice period (typically 90 days for an established relationship), obligations for shipments already in transit or with export permits already issued, and a process for resolving outstanding batch claims before final settlement. Abrupt termination clauses create compliance exposure in a regulated supply chain. Product in transit must still clear narcotics import controls regardless of the commercial relationship's status.
AlphaLeaf is a Montreal-based Health Canada Licensed Producer of indoor-grown, hand-trimmed dried cannabis flower. We hold export authorisation under the Cannabis Act and maintain full batch traceability, ISO/IEC 17025-certified testing, and the GMP documentation records that German, Australian, and Israeli import channels require. If you're structuring a B2B supply relationship with a Canadian LP, we're available to discuss how our compliance documentation and production capacity support your procurement requirements.
Frequently Asked Questions
What should a B2B cannabis supply agreement with a Canadian LP include?
A B2B cannabis supply agreement with a Canadian Licensed Producer should include product specifications (strain, cannabinoid content, format), pricing and currency terms, minimum order quantities, batch COA requirements, delivery and export permit obligations, exclusivity clauses, force majeure provisions covering Health Canada regulatory changes, and dispute resolution jurisdiction. The LP's export authorisation under the Cannabis Act is a non-negotiable representation.
Does a Canadian LP need Health Canada approval to sign a supply agreement with an international importer?
No pre-approval is required to sign a supply agreement, but the LP must hold a valid export authorisation under the Cannabis Act before any product ships. The export permit is applied for on a per-shipment basis from Health Canada. The contract should clarify which party bears responsibility if a permit is delayed.
Can a Canadian LP supply cannabis to both Germany and Australia under a single supply agreement?
Yes, a single master supply agreement can cover multiple destination markets, but each market's regulatory addendum should be separate. German shipments require Bundesopiumstelle narcotic import permits and EU-GMP-aligned documentation. Australian shipments require TGA approval, ODC import permits, and TGO 93-compliant batch records. A single catch-all clause creates ambiguity at customs.
What is an offtake clause in a cannabis supply agreement?
An offtake clause commits the buyer to purchase a minimum quantity over a defined period, typically per quarter or per year. For Canadian LPs, offtake commitments support production planning and strain allocation. For importers, offtake terms secure supply priority and often unlock better per-gram pricing. The clause should specify how shortfalls are handled if the LP cannot meet committed volume.
How are batch rejection and COA disputes handled in a cannabis supply agreement?
The agreement should define acceptable COA parameters for each product (THC range, CBD range, moisture content, microbial limits, residual solvent limits). Designate a mutually agreed third-party ISO/IEC 17025-accredited testing lab for dispute re-testing. Set a rejection claim window (typically 5 to 14 business days after delivery) and specify whether rejected batches are returned, destroyed, or held pending re-test. See the full COA guide for B2B buyers for the standard analyte panels importers should require.
What jurisdiction governs a cannabis supply agreement between a Canadian LP and a German importer?
Most agreements default to Ontario or Quebec law with arbitration in Canada, but German importers may negotiate for ICC arbitration in a neutral seat or for German law to govern the regulatory addendum. Agree on jurisdiction before signing. Cross-border cannabis disputes involve both Health Canada and the destination country's narcotics authority, so ambiguity here is expensive to resolve.
